INTEGRATED BIOTHERAPEUTICS, INC.

Basic Information


Gaithersburg, MD, 20878-1757

Company Profile

n/a

Additional Details

Field Value
DUNS: 601000750
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 16


  1. In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus

    Amount: $599,996.00

    DESCRIPTION (provided by applicant): Staphylococcus aureus is a Gram-positive human pathogen that causes a wide range of infections from skin and soft tissue infections (SSTI) to life threatening seps ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Immunotherapeutics to prevent HCV reinfection

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, l ...

    STTR Phase I 2013 Department of Health and Human Services
  3. Development of Therapeutic Pan-Filovirus Macaque Monoclonal Antibodies

    Amount: $550,414.00

    DESCRIPTION (provided by applicant): Filoviruses, Ebola (EBOV) and Marburg (MARV), are causative agents of sever hemorrhagic fever in humans with case-fatality rates exceeding 88%. Filoviruses, design ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. A novel Structure Based Vaccine for staphylococcal alpha hemolysin

    Amount: $590,778.00

    DESCRIPTION (provided by applicant): Staphylococcus aureus is a gram positive human pathogen that causes a wide range of infections ranging from skin and soft tissue infections to life threatening dis ...

    SBIR Phase I 2012 Department of Health and Human Services
  5. Multi-specific Antibody Therapy by targeting S. aureus toxins and polysaccharides

    Amount: $593,316.00

    DESCRIPTION (provided by applicant): Staphylococcus aureus is a human pathogen that causes a wide range of diseases from skin and soft tissue infections (SSTI) to life threatening sepsis and pneumoni ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Development of a novel second-generation pan-filovirus subunit vaccine

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Filoviruses, Ebola and Marburg, are causative agents of sever hemorrhagic fever in humans with case-fatality rates exceeding 88%. Filoviruses, designated as catego ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. Development of a Panton Valentine Leukocidin bivalent vaccine

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Staphylococcus aureus (S.aureus) is a formidable human pathogen responsible for severe infections in the hospitals and community. S. aureus produces a variety of v ...

    SBIR Phase I 2010 Department of Health and Human Services
  8. Therapeutic Human Hyperimmune Polyclonal Antibodies against Staphylococcal Enterotoxin B

    Amount: $429,456.00

    This Phase II SBIR project addresses the need to develop a treatment for toxic shock induced by staphylococcal Enterotoxin B (SEB), which may be disseminated as an aerosol in a biowarfare scenario. S ...

    SBIR Phase II 2008 ArmyDepartment of DefenseDepartment of Defense
  9. Therapeutic Human Hyperimmune Polyclonal Antibodies against Staphylococcal Enterotoxin B

    Amount: $69,247.00

    Research Proposed: Determine the feasibility of developing human hyperimmune serum (HIS) against staphylococcal enterotoxin B (SEB). PROBLEM/OPPORTUNITY: Staphylococcus aureus is associated with up ...

    SBIR Phase I 2007 ArmyDepartment of DefenseDepartment of Defense
  10. Anti-Id Vaccine for the Prevention of Endotoxemia

    Amount: $50,000.00

    The hemodynamic collapse of septic shock is the leading cause of death in critically ill patients and is the thirteenth leading cause of death overall in the United States; septic shock accounts for a ...

    SBIR Phase I 1993 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government